Hemodialyzer for blood purification

Patent metadata

Field	Value
Publication number	US-11273417-B2
Application number	US-202016851439-A
Country	US
Kind code	B2
Filing date	Apr 17, 2020
Priority date	Feb 6, 2014
Publication date	Mar 15, 2022
Grant date	Mar 15, 2022

Abstract

The present disclosure relates to a dialyzer comprising a bundle of semipermeable hollow fiber membranes which is suitable for blood purification, wherein the dialyzer has an increased ability to remove larger molecules while at the same time it is able to effectively remove small uremic toxins and efficiently retain albumin and larger proteins. The invention also relates to using said dialyzer in hemodialysis.

First claim

The invention claimed is:

1. A method of purifying blood of a patient, said method comprising the step of using a hemodialyzer on the patient, wherein the hemodialyzer comprises a bundle of hollow fiber membranes comprising i) at least one hydrophobic polymer component and ii) at least one hydrophilic polymer component, wherein the membrane has a molecular retention onset (MWRO) of between 9.0 kDa and 14.0 kDa and a molecular weight cut-off (MWCO) of between 55 kDa and 130 kDa as determined by dextran sieving before blood contact of the membrane.

2. The method of claim 1 , wherein the patient is a patient with acute renal failure.

3. The method of claim 1 , wherein the patient is a patient with chronic renal failure.

4. The method of claim 1 , wherein the method is performed at a blood flow rate (QB) in the range of from 200 ml/min to 600 ml/min.

5. The method of claim 1 , wherein the method is performed at a dialysate flow rate (QD) in the range of from 300 ml/min to 1000 ml/min.

6. The method of claim 1 , wherein the method is performed at an ultrafiltration flow rate (UF) in the range of from 0 to 30 ml/min.

7. The method of claim 1 , wherein the method is performed at an ultrafiltration flow rate (UF) in the range of from 0 to 15 ml/min.

8. The method of claim 1 , wherein the membrane provides an effective surface area in the range of from 1.1 m 2 to 2.5 m 2 .

9. The method of claim 1 , wherein the membrane provides an effective surface area in the range of 1.7 m 2 .

10. The method of claim 1 , wherein the hemodialyzer comprises a packing density in the range of from 50% to 65%.

11. The method of claim 1 , wherein the hemodialyzer comprises 80% to 95% crimped fibers and of 5% to 15% non-crimped fibers, relative to the total number of fibers in the bundle.

12. The method of claim 1 , wherein the hemodialyzer comprises 86% to 94% crimped fibers and of 6% to 14% non-crimped fibers, relative to the total number of fibers in the bundle.

13. The method of claim 1 , wherein the hemodialyzer comprises 86% to 92% crimped fibers and of 8% to 14% non-crimped fibers, relative to the total number of fibers in the bundle.

14. The method of claim 1 , wherein the method is performed at a QB between 200 ml/min and 500 ml/min, a QD of 500 ml/min and an UF of 0 ml/min, and wherein the method provides a clearance rate of urea in the range of from between 190 ml/min and 400 ml/min, wherein the clearance rate is determined in vitro according to DIN EN ISO8637:2014.

15. The method of claim 1 , wherein the method is performed at a QB between 200 ml/min and 500 ml/min, a QD of 500 ml/min and an UF of 0 ml/min, and wherein the method provides a clearance rate of creatinine in the range of from between 190 ml/min and 380 ml/min, wherein the clearance rate is determined in vitro according to DIN EN ISO8637:2014.

16. The method of claim 1 , wherein the method is performed at a QB between 200 ml/min and 500 ml/min, a QD of 500 ml/min and an UF of 0 ml/min, and wherein the method provides a clearance rate of phosphate in the range of from between 190 ml/min and 380 ml/min, wherein the clearance rate is determined in vitro according to DIN EN ISO8637:2014.

17. The method of claim 1 , wherein the method is performed at a QB between 200 ml/min and 500 ml/min, a QD of 500 ml/min and an UF of 0 ml/min, and wherein the method provides a clearance rate of vitamin B12 in the range of from between 170 ml/min and 280 ml/min, wherein the clearance rate is determined in vitro according to DIN EN ISO8637:2014.

18. The method of claim 1 , wherein the method is performed at a QB between 200 ml/min and 500 ml/min, a QD of 500 ml/min and an UF of 0 ml/min, and wherein the method provides a clearance rate of inulin in the range of from between 140 ml/min and 240 ml/min, wherein the clearance rate is determined in vitro according to DIN EN ISO8637:2014.

19. The method of claim 1 , wherein the method is performed at a QB between 200 ml/min and 500 ml/min, a QD of 500 ml/min and an UF of 0 ml/min, and wherein the method provides a clearance rate of myoglobin in the range of from between 110 ml/min and 200 ml/min, wherein the clearance rate is determined in vitro according to DIN EN ISO8637:2014.

20. The method of claim 1 , wherein the method is performed at a QB between 200 ml/min and 500 ml/min, a QD of 500 ml/min and an UF of 0 ml/min, and wherein the method provides a clearance rate of cytochrome C in the range of from between 130 ml/min and 200 ml/min, wherein the clearance rate is determined in vitro according to DIN EN ISO8637:2014.

Assignees

• Gambro Lundia Ab

Inventors

• Hornung Markus
• Krause Bernd
• Storr Markus
• Herbst Philipp
• Wochner Arnd
• Boschetti-De-Fierro Adriana
• Voigt Manuel
• Zweigart Carina
• Loercher Joachim
• Buck Reinhold
• Behr Heinrich
• Beck Werner

Classifications

• B01D61/243 Primary

  Dialysis · CPC title

• B01D63/0233

  forming the bundle · CPC title

• B01D71/381

  Polyvinylalcohol · CPC title

• B01D71/441

  Polyvinylpyrrolidone · CPC title

• B01D2325/022

  Asymmetric membranes · CPC title